All In Biotech

Drug Trial Radar · NCT00379041

Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma

Protocol H8 for a Prospective Controlled Trial in Clinical Stage I-II Supradiaphragmatic Hodgkin's Disease. Evaluation of Treatment Efficacy and (Long Term) Toxicity in Three Different Prognostic Subgroups [H8 Trial]

Last checked: Nov 20, 2026Latest source record: Aug 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,158 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,158

Planned (sponsor's estimate)

Start

Sep 1, 1993

Primary completion

Oct 1, 1998

Sponsor

Sponsor type
Research network
First posted
Sep 21, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Primary purpose
Treatment
Who can join
All sexes, from 15 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Radiation therapy uses high-energy x-rays to kill cancer cells. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with combination chemotherapy may kill more cancer cells. It is not yet known whether radiation therapy is more effective with or without combination chemotherapy in treating patients with Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it works with or without combination chemotherapy in treating patients with previously untreated stage I or stage II Hodgkin's lymphoma.

Conditions

  • Lymphoma

Interventions

  • bleomycin sulfateBiological

  • doxorubicin hydrochlorideDrug

  • mechlorethamine hydrochlorideDrug

  • prednisoneDrug

  • procarbazine hydrochlorideDrug

  • vinblastine sulfateDrug

  • vincristine sulfateDrug

  • radiation therapyRadiation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival
  2. Reduction of late treatment-related toxicity
  3. Maintenance of failure-free survival rate

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.